Literature DB >> 27638599

Intrathecal administration of AAV/GALC vectors in 10-11-day-old twitcher mice improves survival and is enhanced by bone marrow transplant.

Subha Karumuthil-Melethil1, Michael S Marshall2, Clifford Heindel1, Benas Jakubauskas2, Ernesto R Bongarzone2, Steven J Gray3,4.   

Abstract

Globoid cell leukodystrophy (GLD), or Krabbe disease, is an autosomal recessive neurodegenerative disease caused by the deficiency of the lysosomal enzyme galactocerebrosidase (GALC). Hematopoietic stem cell transplantation (HSCT) provides modest benefit in presymptomatic patients but is well short of a cure. Gene transfer experiments using viral vectors have shown some success in extending the survival in the mouse model of GLD, twitcher mice. The present study compares three single-stranded (ss) AAV serotypes, two natural and one engineered (with oligodendrocyte tropism), and a self-complementary (sc) AAV vector, all packaged with a codon-optimized murine GALC gene. The vectors were delivered via a lumbar intrathecal route for global CNS distribution on PND10-11 at a dose of 2 × 10(11) vector genomes (vg) per mouse. The results showed a similar significant extension of life span of the twitcher mice for all three serotypes (AAV9, AAVrh10, and AAV-Olig001) as well as the scAAV9 vector, compared to control cohorts. The rAAV gene transfer facilitated GALC biodistribution and detectable enzymatic activity throughout the CNS as well as in sciatic nerve and liver. When combined with BMT from syngeneic wild-type mice, there was significant improvement in survival for ssAAV9. Histopathological analysis of brain, spinal cord, and sciatic nerve showed significant improvement in preservation of myelin, with ssAAV9 providing the greatest benefit. In summary, we demonstrate that lumbar intrathecal delivery of rAAV/mGALCopt can significantly enhance the life span of twitcher mice treated at PND10-11 and that BMT synergizes with this treatment to improve the survival further.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  AAV; GALC; Krabbe disease; gene therapy; globoid cell leukodystrophy; intrathecal

Mesh:

Substances:

Year:  2016        PMID: 27638599      PMCID: PMC5028109          DOI: 10.1002/jnr.23882

Source DB:  PubMed          Journal:  J Neurosci Res        ISSN: 0360-4012            Impact factor:   4.164


  44 in total

Review 1.  Immune responses to gene therapy vectors: influence on vector function and effector mechanisms.

Authors:  N Bessis; F J GarciaCozar; M-C Boissier
Journal:  Gene Ther       Date:  2004-10       Impact factor: 5.250

2.  Intravenous injection of AAVrh10-GALC after the neonatal period in twitcher mice results in significant expression in the central and peripheral nervous systems and improvement of clinical features.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; Alice Luddi; Mark T Curtis; David A Wenger
Journal:  Mol Genet Metab       Date:  2014-12-11       Impact factor: 4.797

3.  Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis.

Authors:  D M McCarty; P E Monahan; R J Samulski
Journal:  Gene Ther       Date:  2001-08       Impact factor: 5.250

4.  An apoptotic depletion of oligodendrocytes in the twitcher, a murine model of globoid cell leukodystrophy.

Authors:  M Taniike; I Mohri; N Eguchi; D Irikura; Y Urade; S Okada; K Suzuki
Journal:  J Neuropathol Exp Neurol       Date:  1999-06       Impact factor: 3.685

5.  RH10 provides superior transgene expression in mice when compared with natural AAV serotypes for neonatal gene therapy.

Authors:  Chuhong Hu; Ronald W Busuttil; Gerald S Lipshutz
Journal:  J Gene Med       Date:  2010-09       Impact factor: 4.565

6.  Long-term Improvements in Lifespan and Pathology in CNS and PNS After BMT Plus One Intravenous Injection of AAVrh10-GALC in Twitcher Mice.

Authors:  Mohammad A Rafi; Han Zhi Rao; Paola Luzi; David A Wenger
Journal:  Mol Ther       Date:  2015-09-02       Impact factor: 11.454

7.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

8.  The Twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease).

Authors:  T Kobayashi; T Yamanaka; J M Jacobs; F Teixeira; K Suzuki
Journal:  Brain Res       Date:  1980-12-08       Impact factor: 3.252

9.  Globoid cell leucodystrophy (Krabbe's disease): deficiency of galactocerebroside beta-galactosidase.

Authors:  K Suzuki; Y Suzuki
Journal:  Proc Natl Acad Sci U S A       Date:  1970-06       Impact factor: 11.205

Review 10.  Adeno-associated virus: from defective virus to effective vector.

Authors:  Manuel A F V Gonçalves
Journal:  Virol J       Date:  2005-05-06       Impact factor: 4.099

View more
  24 in total

1.  Efficient CNS targeting in adult mice by intrathecal infusion of single-stranded AAV9-GFP for gene therapy of neurological disorders.

Authors:  K Bey; C Ciron; L Dubreil; J Deniaud; M Ledevin; J Cristini; V Blouin; P Aubourg; M-A Colle
Journal:  Gene Ther       Date:  2017-04-20       Impact factor: 5.250

2.  An Engineered Galactosylceramidase Construct Improves AAV Gene Therapy for Krabbe Disease in Twitcher Mice.

Authors:  Xiufang Pan; Scott A Sands; Yongping Yue; Keqing Zhang; Steven M LeVine; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2019-07-18       Impact factor: 5.695

3.  Long-Term Improvement of Neurological Signs and Metabolic Dysfunction in a Mouse Model of Krabbe's Disease after Global Gene Therapy.

Authors:  Michael S Marshall; Yazan Issa; Benas Jakubauskas; Monika Stoskute; Vince Elackattu; Jeffrey N Marshall; Wil Bogue; Duc Nguyen; Zane Hauck; Emily Rue; Subha Karumuthil-Melethil; Violeta Zaric; Maarten Bosland; Richard B van Breemen; Maria I Givogri; Steven J Gray; Stephen J Crocker; Ernesto R Bongarzone
Journal:  Mol Ther       Date:  2018-01-17       Impact factor: 11.454

Review 4.  Comparison of high-dose intracisterna magna and lumbar puncture intrathecal delivery of AAV9 in mice to treat neuropathies.

Authors:  Rachel M Bailey; Alejandra Rozenberg; Steven J Gray
Journal:  Brain Res       Date:  2020-04-11       Impact factor: 3.252

5.  Krabbe disease successfully treated via monotherapy of intrathecal gene therapy.

Authors:  Allison M Bradbury; Jessica H Bagel; Duc Nguyen; Erik A Lykken; Jill Pesayco Salvador; Xuntian Jiang; Gary P Swain; Charles A Assenmacher; Ian J Hendricks; Keiko Miyadera; Rebecka S Hess; Arielle Ostrager; Patricia ODonnell; Mark S Sands; Daniel S Ory; G Diane Shelton; Ernesto R Bongarzone; Steven J Gray; Charles H Vite
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

6.  AAV-CNS matters turn from gray to white.

Authors:  Aaron Mitchell-Dick; Aravind Asokan
Journal:  Mol Ther       Date:  2021-04-22       Impact factor: 11.454

Review 7.  Mechanisms of demyelination and neurodegeneration in globoid cell leukodystrophy.

Authors:  M Laura Feltri; Nadav I Weinstock; Jacob Favret; Narayan Dhimal; Lawrence Wrabetz; Daesung Shin
Journal:  Glia       Date:  2021-04-14       Impact factor: 7.452

8.  Waning efficacy in a long-term AAV-mediated gene therapy study in the murine model of Krabbe disease.

Authors:  Gregory J Heller; Michael S Marshall; Yazan Issa; Jeffrey N Marshall; Duc Nguyen; Emily Rue; Koralege C Pathmasiri; Miriam S Domowicz; Richard B van Breemen; Leon M Tai; Stephanie M Cologna; Stephen J Crocker; Maria I Givogri; Mark S Sands; Ernesto R Bongarzone
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

9.  Enhanced Efficacy and Increased Long-Term Toxicity of CNS-Directed, AAV-Based Combination Therapy for Krabbe Disease.

Authors:  Yedda Li; Christopher A Miller; Lauren K Shea; Xuntian Jiang; Miguel A Guzman; Randy J Chandler; Sai M Ramakrishnan; Stephanie N Smith; Charles P Venditti; Carole A Vogler; Daniel S Ory; Timothy J Ley; Mark S Sands
Journal:  Mol Ther       Date:  2021-01-01       Impact factor: 11.454

10.  Development of Intrathecal AAV9 Gene Therapy for Giant Axonal Neuropathy.

Authors:  Rachel M Bailey; Diane Armao; Sahana Nagabhushan Kalburgi; Steven J Gray
Journal:  Mol Ther Methods Clin Dev       Date:  2018-02-15       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.